{"DataElement":{"publicId":"5981612","version":"1","preferredName":"Invasive Breast Carcinoma Mitotic Count Nottingham Histologic Score Number","preferredDefinition":"The number of mitoses per 10 high power fields using  the Nottingham scoring system.","longName":"IBC_MICT_NOTSC_NUM","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"5979452","version":"1","preferredName":"Invasive Breast Carcinoma Mitotic Count","preferredDefinition":"A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women._The number of mitoses identified under the microscope in tumors.  It is one of the parameters that determine the grade of malignant tumors.  The method of counting varies, according to the specific tumor examined.  Usually the mitotic count is determined based on the number of mitoses per high power field (40X) or 10 high power fields.","longName":"2431278v1.0:2431222v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2431278","version":"1","preferredName":"Invasive Breast Carcinoma","preferredDefinition":"A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women. --2003","longName":"C9245","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Invasive Breast Carcinoma","conceptCode":"C9245","definition":"A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DCF1A1-FAC7-3A7D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2431222","version":"1","preferredName":"Mitotic Count","preferredDefinition":"definition pending","longName":"C47864","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitotic Count","conceptCode":"C47864","definition":"The number of mitoses identified under the microscope in tumors.  It is one of the parameters that determine the grade of malignant tumors.  The method of counting varies, according to the specific tumor examined.  Usually the mitotic count is determined based on the number of mitoses per high power field (40X) or 10 high power fields.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DCE31E-478E-3314-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"592A743E-A669-487D-E053-F662850A9518","latestVersionIndicator":"Yes","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"HARTLEYG","dateModified":"2018-06-06","changeDescription":"9/19/17 tt released.  9/14/17 tt New DEC, added CSI per Round 5 finalization task; replaces DEC 2431349.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5981611","version":"1","preferredName":"Nottingham Histologic Score Mitotic Count Number","preferredDefinition":"A numeric representation combining three histologic reporting elements, tubule formation, nuclear pleomorphism and mitotic count, to determine the grade of breast cancer.  The Nottingham Score is a factor in determining the Nottingham Prognostic Index._The number of mitoses identified under the microscope in tumors.  It is one of the parameters that determine the grade of malignant tumors.  The method of counting varies, according to the specific tumor examined.  Usually the mitotic count is determined based on the number of mitoses per high power field (40X) or 10 high power fields._A numeral or string of numerals expressing value, quantity, or identification.","longName":"5981611v1.0","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":"1","maxLength":"2","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5981835","version":"1","preferredName":"Nottingham Score Mitotic Count Number","preferredDefinition":"A numeric representation combining three histologic reporting elements, tubule formation, nuclear pleomorphism and mitotic count, to determine the grade of breast cancer.  The Nottingham Score is a factor in determining the Nottingham Prognostic Index.:The number of mitoses identified under the microscope in tumors.  It is one of the parameters that determine the grade of malignant tumors.  The method of counting varies, according to the specific tumor examined.  Usually the mitotic count is determined based on the number of mitoses per high power field (40X) or 10 high power fields.:A numeral or string of numerals expressing value, quantity, or identification. ","longName":"C25595:C47864:C25337","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nottingham Score","conceptCode":"C25595","definition":"A numeric representation combining three histologic reporting elements, tubule formation, nuclear pleomorphism and mitotic count, to determine the grade of breast cancer. The Nottingham Score is a factor in determining the Nottingham Prognostic Index.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Mitotic Count","conceptCode":"C47864","definition":"The number of mitoses identified under the microscope in tumors.  It is one of the parameters that determine the grade of malignant tumors.  The method of counting varies, according to the specific tumor examined.  Usually the mitotic count is determined based on the number of mitoses per high power field (40X) or 10 high power fields.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Number","conceptCode":"C25337","definition":"A numeral or string of numerals expressing value, quantity, or identification.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"599F7272-6A47-456A-E053-F662850A77CE","latestVersionIndicator":"Yes","beginDate":"2017-09-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-20","modifiedBy":"ONEDATA","dateModified":"2017-09-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"597D0C90-30B6-349D-E053-F662850A6440","latestVersionIndicator":"Yes","beginDate":"2017-09-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-18","modifiedBy":"HARTLEYG","dateModified":"2018-06-06","changeDescription":"9/19/17 tt released.  9/18/17 tt New VD to incorporate 2017 CAP Nottingham Score guidelines, added CSI per Round 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5506116","version":"1","longName":"Pathology","context":"MCL","ClassificationSchemeItems":[{"publicId":"5855640","version":"1","longName":"Breast Pathology","context":"MCL"}]},{"publicId":"5635300","version":"1","longName":"Case Report Form (CRF) Modules","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"5915898","version":"1","longName":"Microscopic Pathology","context":"NCI Standards"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Instructional Text","type":"REFERENCE","description":"CAP Nottingham Score 2017: This element is not required for accreditation purposes and considered optional; may be clinically important but is not yet validated or regularly used in patient management.","url":"http://www.cap.org/","context":"NCI Standards"},{"name":"Number of mitoses per 10 high","type":"Preferred Question Text","description":"Number of mitoses per 10 high-power fields","url":null,"context":"NCI Standards"}],"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"597CB278-81F7-275B-E053-F662850AC8DE","latestVersionIndicator":"Yes","beginDate":"2017-09-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-18","modifiedBy":"COLBERTM","dateModified":"2022-03-18","changeDescription":"9/20/17 tt released. 9/18/17 tt New CDE to incorporate 2017 CAP Nottingham Score guidelines, added CSI per Round 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}